joint efforts will form best practices for non-profit health organizations to leverage patient self-reporting with the goal of advancing science, treatment and quality of life.
This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.